"trastuzumab refractory" trang 3 - tải miễn phí từ tailieunhanh
báo cáo khoa học:

báo cáo khoa học: "Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting Her 2neu positive localized Gastric Adenocarcinoma?"
18    52    0
báo cáo khoa học:

báo cáo khoa học: "Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report"
4    91    0
Báo cáo y học:

Báo cáo y học: " Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature"
4    48    0
Tóm tắt Luận án tiến sĩ Y học: Điều trị tân bổ trợ thành công bệnh nhân ung thư vú giai đoạn muộn tại Trung tâm Y học hạt nhân và Ung bướu, Bệnh viện Bạch Mai

Tóm tắt Luận án tiến sĩ Y học: Điều trị tân bổ trợ thành công bệnh nhân ung thư vú giai đoạn muộn tại Trung tâm Y học hạt nhân và Ung bướu, Bệnh viện Bạch Mai
48    100    0
Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy
8    110    0
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
10    77    0
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis
15    70    0
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
8    61    1
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review
8    84    1
Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review
8    59    1
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial
6    60    1
A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: Design of the CARDAPAC study

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: Design of the CARDAPAC study
11    40    1
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: A case report

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: A case report
5    35    1
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
14    62    1
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
10    49    1
A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study
15    70    1
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
14    39    1
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
7    38    1
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
11    55    1
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neupositive breast cancer cells

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neupositive breast cancer cells
15    37    1